Polymeric nanogel formulations of nucleoside analogs

被引:55
作者
Vinogradov, Serguei V. [1 ,2 ]
机构
[1] Univ Nebraska, Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA
[2] Ctr Drug Delivery & Nanaomed, Omaha, NE 68198 USA
关键词
accumulation enhancement; drug delivery; nucleoside 5'-triphosphates; polymeric microgels; structural modification; triggered drug release; vectorisation;
D O I
10.1517/17425247.4.1.5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nanogels are colloidal microgel carriers that have been recently introduced as a prospective drug delivery system for nucleotide therapeutics. The crosslinked protonated polymer network of nanogels binds oppositely charged drug molecules, encapsulating them into submicron particles with a core-shell structure. The nanogel network also provides a suitable template for chemical engineering, surface modification and vectorisation. This review reveals recent attempts to develop novel drug formulations of nanogels with antiviral and antiproliferative nucleoside analogs in the active form of T-triphosphates, discusses structural approaches to the optimisation of nanogel properties, and discusses the development of targeted nanogel drug formulations for systemic administration. Notably, nanogels can improve the CNS penetration of nucleoside analogs that are otherwise restricted from passing across the blood-brain barrier. The latest findings reviewed here demonstrate an efficient intracellular release of nucleoside analogs, encouraging further applications of nanogel carriers for targeted drug delivery.
引用
收藏
页码:5 / 17
页数:13
相关论文
共 79 条
[1]   PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[2]  
BASHFORD CL, 1986, J BIOL CHEM, V261, P9300
[3]   INHIBITION OF HIV IN-VITRO BY ANTIVIRAL DRUG-TARGETING USING NANOPARTICLES [J].
BENDER, A ;
SCHAFER, V ;
STEFFAN, AM ;
ROYER, C ;
KREUTER, J ;
RUBSAMENWAIGMANN, H ;
VONBRIESEN, H .
RESEARCH IN VIROLOGY, 1994, 145 (3-4) :215-220
[4]   Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro [J].
Bender, AR ;
vonBriesen, H ;
Kreuter, J ;
Duncan, IB ;
RubsamenWaigmann, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1467-1471
[5]   The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy [J].
Borst, P ;
Balzarini, J ;
Ono, N ;
Reid, G ;
de Vries, H ;
Wielinga, P ;
Wijnholds, J ;
Zelcer, N .
ANTIVIRAL RESEARCH, 2004, 62 (01) :1-7
[6]  
Brachwitz H, 1998, J LIPID RES, V39, P162
[7]   Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? [J].
Brinkman, K ;
Kakuda, TN .
CURRENT OPINION IN INFECTIOUS DISEASES, 2000, 13 (01) :5-11
[8]  
Bromberg Lev, 2005, Expert Opin Drug Deliv, V2, P1003, DOI 10.1517/17425247.2.6.1003
[9]   Therapeutic potential of nanoparticulate systems for macrophage targeting [J].
Chellat, F ;
Merhi, Y ;
Moreau, A ;
Yahia, L .
BIOMATERIALS, 2005, 26 (35) :7260-7275
[10]   Side-effects of a systemic injection of linear polyethylenimine-DNA complexes [J].
Chollet, P ;
Favrot, MC ;
Hurbin, A ;
Coll, JL .
JOURNAL OF GENE MEDICINE, 2002, 4 (01) :84-91